September 6, 2024 – Tampa, FL – MitoSense, holder of an exclusive license on groundbreaking technology from the Elliott Mitochondria Research Center, is thrilled to support the upcoming benefit concert featuring John Driskell Hopkins of the multi-Grammy Award-winning Zac Brown Band. The event is set to take place on Friday, September 20, 2024, at 6:30 PM at the USF School of Music in Tampa, Florida.
This extraordinary evening aims to raise crucial funds for the Elliott Mitochondria Research Center (EMRC), which collaborates closely with the James A. Haley Veteran's Hospital to pioneer new therapeutic treatments for Amyotrophic Lateral Sclerosis (ALS) and Traumatic Brain Injury (TBI). Through this unique collaboration, EMRC leverages the clinical expertise and resources of the hospital to drive forward cutting-edge research, offering hope to countless individuals affected by these challenging conditions.
“We are incredibly excited to support the Elliott Mitochondria Research Center's dedication to advancing therapies for ALS and TBI,” said Van Hipp, Chairman at MitoSense. “Their work aligns perfectly with our mission to leverage innovative technology for groundbreaking medical solutions. The benefit concert is an excellent opportunity to engage with the community and raise awareness for these vital causes.”
Event Details:
Date: September 20, 2024
Time: 6:30 PM
Location: USF School of Music, 3755 USF Holly Dr., Tampa, FL 33620
Tickets: $100 each, available through Ticketmaster
All proceeds from the event will support the Elliott Mitochondria Research Center's mission to provide hope and advanced medical care through innovative research and treatments.
For more information about sponsorship opportunities, please contact: info@mitosenseinc.com.
Join us for an unforgettable evening of music and support for a brighter future!
About MitoSense
MitoSense is a pioneering company in the field of mitochondrial research and therapy. Through our exclusive partnership with the Elliott Mitochondria Research Center, we are at the forefront of developing technologies that offer new hope for treating ALS, TBI, and other mitochondrial disorders.